Sanofi

Q4 2024 13F Holdings

  • Location
    paris, I0
  • Num holdings

    9

  • Value ($000)

    $174,360

  • Date Filed
    02/14/2025
  • Form type
    13F-HR
  • CIK
    0001121404
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2024 to
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

MeiraGTx Holdings plc

COM
G59665102
$74.28M
43 %

12,197,737

NVV1
NVV1

Novavax

COM NEW
670002401
$55.32M
32 %

6,880,481

INBX
INBX

Inhibrx Biosciences, Inc.

COM
45720N103
$17.83M
10 %

1,157,926

ANAB
ANAB

AnaptysBio

COM
032724106
$10.88M
6 %

821,917

IGMS
IGMS

IGM Biosciences

COM
449585108
$8.79M
5 %

1,438,975

ELDN
ELDN

Eledon

COM
28617K101
$3.36M
2 %

814,980

---

LAVA Therapeutics N.V.

SHS
N51517105
$1.83M
1 %

1,919,455

INZY
INZY

Inozyme, Inc

COM
45790W108
$1.23M
1 %

443,255

QTTB
QTTB

Q32 Bio Inc.

COM
746964105
$839.65K
1 %

244,083

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 9 of 9